Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 501.50M | 537.72M | 687.41M | 614.30M | 503.01M |
Gross Profit | 147.50M | 164.61M | 168.45M | 170.23M | 134.11M |
EBITDA | -52.06M | -75.65M | -161.41M | -214.71M | -101.65M |
Net Income | -83.05M | -154.65M | -241.97M | -296.54M | -196.43M |
Balance Sheet | |||||
Total Assets | 1.26B | 1.40B | 934.45M | 946.85M | 954.64M |
Cash, Cash Equivalents and Short-Term Investments | 797.70M | 856.13M | 351.76M | 364.91M | 419.87M |
Total Debt | 574.47M | 603.44M | 573.44M | 456.28M | 446.23M |
Total Liabilities | 892.31M | 964.28M | 1.38B | 1.21B | 1.09B |
Stockholders Equity | 363.31M | 428.14M | -451.98M | -274.55M | -132.99M |
Cash Flow | |||||
Free Cash Flow | 21.56M | -24.42M | -81.17M | -101.77M | -124.13M |
Operating Cash Flow | 21.56M | -20.16M | -73.83M | -83.38M | -17.30M |
Investing Cash Flow | 110.45M | -146.60M | -8.45M | -5.47M | -195.16M |
Financing Cash Flow | -56.56M | 504.77M | 64.62M | 64.90M | 216.29M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | HK$18.74B | 35.05 | 28.81% | 0.89% | 14.99% | 31.70% | |
59 Neutral | HK$15.37B | 5.76 | -7.44% | 4.08% | 11.55% | -28.15% | |
54 Neutral | HK$766.11M | ― | ― | ― | ― | ||
47 Neutral | HK$2.27B | ― | -2.19% | ― | 5.32% | 89.43% | |
45 Neutral | HK$760.40M | ― | -18.64% | ― | 41.62% | -22.27% | |
45 Neutral | HK$5.06B | ― | -2.97% | ― | 11.00% | 56.87% | |
44 Neutral | HK$1.35B | ― | -18.19% | ― | -24.50% | -93.44% |
Xikang Cloud Hospital Holdings Inc. announced its decision to use idle proceeds from its global offering for cash management by investing in high-security, liquid wealth management products. This strategic move, involving up to US$40 million, is intended to enhance fund usage efficiency and protect shareholder interests without affecting the company’s normal operations or the intended use of proceeds.
Xikang Cloud Hospital Holdings Inc. held its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed. These included the adoption of financial statements, re-election of directors, re-appointment of auditors, and granting mandates for share issuance and repurchase. The adoption of the ninth amended Memorandum and Articles of Association was also approved, indicating strategic governance updates.
Xikang Cloud Hospital Holdings Inc. announced a connected transaction involving the disposal of equity interests in a target company and a capital increase arrangement. Xikang Healthcare Technology, a subsidiary of Xikang Cloud Hospital, agreed to transfer its equity interest in the target company to Neutech, while Neutech will also participate in a capital increase for the target company. This transaction will result in a dilution of Xikang Cloud Hospital’s shareholding in the target company, and it complies with the reporting requirements under the Listing Rules, though it is exempt from independent shareholders’ approval.
Xikang Cloud Hospital Holdings Inc. has announced its Annual General Meeting to be held on May 22, 2025, where key resolutions will be discussed, including the adoption of financial statements, re-election of directors, and re-appointment of auditors. The meeting will also consider granting a mandate to the company’s directors to issue additional shares, potentially impacting the company’s capital structure and shareholder value.
Xikang Cloud Hospital Holdings Inc. announced the resignation of Dr. CHEN Lianyong as a non-executive director and member of the Audit and Strategy Committees due to other work arrangements, effective April 18, 2025. The company also appointed Dr. QI Guoxian as a new member of the Audit Committee, reflecting ongoing adjustments in its governance structure.
Xikang Cloud Hospital Holdings Inc., formerly known as Neusoft Xikang Holdings Inc., has announced the composition of its board of directors and their respective roles. The board comprises a mix of executive, non-executive, and independent non-executive directors, with Liu Jiren serving as the chairperson. This announcement provides clarity on the governance structure of the company, which is crucial for stakeholders and investors as it outlines the leadership responsible for strategic decisions and oversight.